On April 21, 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported positive data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 17–22 at the San Diego Convention Center in San Diego, California.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster is summarized below and linked here: View Source
Title: Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor Responses
Session Category: Clinical Research
Session Title: Vaccines and Other Immunomodulatory Agents
Session: 4/21/2026 2:00-5:00 PM
Location: Poster Section 49
Poster Board Number: 12
Poster Number: 6701
Summary: Bria-OTS+ is a personalized, off-the-shelf, next-generation genetically engineered whole-cell cancer immunotherapy platform designed to enhance efficacy and safety. Our results demonstrate that Bria-OTS+ activates key components of both the innate and adaptive immune systems to broadly target and destroy cancer cells across solid tumors. These effects include coordinated activation of CD4⁺ and CD8⁺ T cells, NK cells, NKT cells, dendritic cells, and B cells, together with increased cytokine release and sustained immune competence without exhaustion—helping address an important mechanism of cancer progression.
Data presented includes the following:
Rapid activation of innate and adaptive immune responses: Bria-BRES+ (breast cancer) and Bria-PROS+ (prostate cancer) drove early activation and proliferation of key immune cells including CD4+ and CD8+ T cells, NK cells, and NKT cells, enhanced cytotoxic activity against parental tumor targets, and increased CD80/CD86 expression on dendritic and B cells, consistent with improved antigen-presentation.
Sustained, long-lasting and targeted anti-tumor activity: Bria-BRES+ and Bria-PROS+ generated durable cytokine responses and maintained cytotoxic, serial killing activity through repeated cancer cell challenges without evidence of functional exhaustion. Bria-OTS+ also showed limited induction of immunosuppressive cell populations including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs).
Broad tumor recognition may reduce escape risk: Bria-BRES+ and Bria-PROS+ cells demonstrated anti-tumor activity against multiple tumor targets, supporting the potential of Bria-OTS+ to drive broad, cross-tumor immune responses, reduce immune escape, and limit cancer progression.
Bria-OTS+ proposed mechanism of action: Following intradermal administration, Bria-OTS+ is designed to activate T cells and NK cells directly, while professional antigen-presenting cells (APCs) take up tumor specific antigens, migrate to regional lymph nodes and prime tumor-specific T cells to drive a systemic anti-tumor immune response.
Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer, commented, "We are thrilled with our data showing early, strong, and long-lasting anti-cancer activity of Bria-OTS+ in multiple cancer models, boosting the immune system response, and potentially overcoming common cancer cell resistance mechanisms. Our findings strongly support targeted anti-cancer effects of Bria-OTS+ and warrant additional testing of the Bria-OTS+ platform in clinical settings."
"Based on these promising preclinical findings, we are advancing Bria-OTS+ with the goal of entering the clinic for our first indications of metastatic breast cancer and prostate cancer later this year, with additional indications (lung cancer and melanoma) planned for 2027," added Dr. William V. Williams, BriaCell’s President and CEO.
(Press release, BriaCell Therapeutics, APR 21, 2026, View Source [SID1234664673])